Joan Blade, MD, PhD, Hospital Clínic de Barcelona, Barcelona, Spain, talks on the 2020 International Symposium on Amyloidosis and the utilization of virtual techniques to continue the amyloidosis conversation during the pandemic.
Anti-interleukin-6 receptor, tocilizumab, has demonstrated improvements in the clinical symptoms of patients with AA amyloidosis, being associated with regression of amyloid deposition. Luis Quintana, MD, PhD, Hospital Clínic de Barcelona, Barcelona, Spain discusses the use of this agent for AA amyloidosis.
Oliver Charles Cohen, MD, University College London Hospitals NHS Foundation Trust, London, UK, talks on the value of screening biopsies in light-chain (AL) and transthyretin (ATTR) amyloidosis.
Data has shown that cardiac transplantation can have very positive outcomes for AL amyloidosis patients. Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, discusses the use of solid organ transplant in amyloidosis.
Many therapies for AL amyloidosis are derived from treatments commonly used for multiple myeloma, with initial trials investigating melphalan and prednisone. In this video Joel Buxbaum, MD, Scripps Research, La Jolla, CA, tells us about the evolution of AL amyloidosis therapy, delineating the trend of regimens that parallel that of multiple myeloma and commenting on …
ISA 2020 | The Evolution of AL Amyloidosis Therapy Read More »
Joan Blade, MD, PhD, Hospital Clínic de Barcelona, Barcelona, Spain, discusses supportive care in AL amyloidosis. Issues such as kidney, gastrointestinal, and cardiac involvement can all contribute to a reduction in patient quality of life.
Renal dysfunction is a common complication of AL amyloidosis. Oliver Charles Cohen, MD, University College London Hospitals NHS Foundation Trust, London, UK, talks on the impact and importance of post-renal transplantation hematological response assessment in AL amyloidosis.
Joel Buxbaum, MD, Scripps Research, La Jolla, CA, talks on improvements in amyloidosis management in recent years, commenting on the progression of options and outcomes in AL amyloidosis.
There has been a recent effort to increase the number of prognostics available for amyloidosis clinicians. Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, talks on this and some of the new prognostic markers in AL amyloidosis such as growth differentiation factor-15 (GDF15) and D-dimers.
Eli Muchtar, MD, Mayo Clinic, Rochester, MN, discusses his recent abstract on new organ response criteria for immunoglobulin light chain (AL) amyloidosis. The use of these new criteria will allow for the further stratification of patients with AL amyloidosis.